Company / SG&A per Share
LENZ Therapeutics, Inc. SG&A per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$3.31
FY2025
5-year range
$0.60 / $6.60
FY2021-FY2025
Trend
+144.6%
vs FY2024
Sector context
#54 of 210
Health Care
What the data says
At $3.31, LENZ Therapeutics, Inc.'s sg&a per share ranks #157 of 210 in the Health Care sector. SG&A per Share has fluctuated over the past 6 years, ranging from $0.60 in FY2022 to $6.60 in FY2023.
Based on SEC 10-K filings.
3.31 in FY2025 with a 5-year CAGR of +11.6%.
Improved from $6.60 to $3.31 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +76.9%
- 5-Year CAGR
- +11.6%
- 10-Year CAGR
- -
Sector benchmark
#157 of 210 in Health CareTop 74% of 210This company $3.31 Sector average $40.75
▼
-91.9% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share increased 144.6% year-over-year.
- Ranks #54 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2023.
- Lowest sg&a per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.31 | +144.6% |
| FY2024 | $1.35 | -79.5% |
| FY2023 | $6.60 | +1002.0% |
| FY2022 | $0.60 | -23.1% |
| FY2021 | $0.78 | -59.4% |
| FY2020 | $1.92 | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026